Drug Profile
PLX 73086
Alternative Names: AC-708; PLX73086Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Ambit Biosciences Corporation
- Developer Plexxikon
- Class Antineoplastics
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Giant cell tumour of tendon sheath
Most Recent Events
- 27 Apr 2018 Discontinued - Phase-I for Giant cell tumour of tendon sheath (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (PO)
- 01 Jan 2018 Plexxikon discontinues a phase-I clinical trials in Giant cell tumour of tendon sheath (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (PO) (NCT02673736)
- 01 Feb 2016 Phase-I clinical trials in Giant cell tumour of tendon sheath (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (PO) (NCT02673736)